Calendar of Events

Unpack the latest in VEGF×PD-1 biology, target pairing, and binding optimization to drive next-gen bispecifics. With ivonescimab showing a 49% PFS gain in NSCLC, momentum is building. As bispecifics expand into autoimmune and TCEs, the 16th World Bispecific Summit offers real-world insights to overcome translational hurdles and accelerate smarter, safer therapeutic design.

The 9th Neuropsychiatric Drug Development Summit is the leading industry forum dedicated to accelerating innovation in mental health therapeutics. Bringing together more than 150 leaders from biopharma, biotech, academia, clinical research, and regulatory organisations, the summit explores the latest advances in precision psychiatry, neuroplastogens, biomarkers, patient stratification, and translational neuroscience. With a focus on overcoming the challenges of neuropsychiatric drug development and improving clinical outcomes, the event provides a unique platform for collaboration, scientific exchange, and the advancement of next-generation therapies for conditions including depression, schizophrenia, PTSD, addiction, and anxiety disorders.

With clinical momentum accelerating across autoimmune and oncology cell therapies, the 11th CAR-TCR Summit unites the field to reflect on a decade of progress and tackle today’s biggest challenges. From solid tumor targeting to scalable manufacturing and biomarker development, join experts across discovery to late-stage development to gain practical solutions and shape the future of cell therapy.

BioJapan 2026 is one of Asia’s largest and most established biotechnology partnering events, bringing together pharmaceutical companies, biotech innovators, researchers, investors, and healthcare organisations from around the world. Taking place in Yokohama, Japan, the event combines exhibitions, expert-led seminars, and a dedicated partnering platform designed to facilitate strategic collaborations, licensing discussions, and business development opportunities. Celebrating its 40th anniversary in 2026, BioJapan continues to be a key meeting point for organisations looking to drive innovation across biotechnology, drug discovery, regenerative medicine, and digital health.

The Oligonucleotide Therapeutics Society (OTS) Annual Meeting 2026 brings together leading researchers, clinicians, biotech innovators, and pharmaceutical companies to explore the latest advances in oligonucleotide-based medicines. Taking place in Denver, Colorado, the conference serves as a premier forum for discussing breakthroughs in RNA therapeutics, gene silencing technologies, delivery systems, and nucleic acid drug development. With a strong emphasis on scientific innovation and translational research, OTS provides an invaluable opportunity for collaboration, networking, and knowledge sharing across the rapidly evolving oligonucleotide therapeutics landscape.

Solidifying ADCs as Standard of Care Therapies by De-Risking Differentiated Payload MoAs Beyond Topo1, Elevating ADCs to Deliver Wider Impact in the Clinical Landscape & Adapting Manufacturing Efficiency for Novel & Cost-Effective ADCs

BIO-Europe 2026 is Europe’s premier biopharma partnering event, bringing together biotechnology companies, pharmaceutical leaders, investors, and business development professionals from across the global life sciences ecosystem. Taking place in Cologne, Germany, from 9-11 November 2026, the conference provides a dedicated platform for strategic networking, one-to-one partnering meetings, and industry insights. With a strong focus on licensing, investment, collaboration, and business growth, BIO-Europe is widely regarded as one of the most important events for organisations looking to forge new partnerships and advance innovation across the biotechnology sector.

PEGS Europe 2026 is one of Europe’s leading conferences for biologics, bringing together more than 1,500 scientists, drug developers, and industry leaders to explore the latest advances in protein and antibody engineering. Taking place in Lisbon, the event covers key areas including multispecific antibodies, AI-driven protein design, next-generation therapeutics, immunoengineering, and biologics development. With a strong focus on innovation and collaboration, PEGS Europe provides a valuable platform for networking, scientific exchange, and discovering emerging technologies shaping the future of drug development.

Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry’s greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment.

The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe’s next generation of targeted radiopharmaceuticals.